Insulin Therapy News

• EASD 2018System Improves Less-Than-Ideally Controlled Type 1 Diabetes Partially automated insulin delivery system increases time spent in target glucose range and minimizes hypoglycemia in patients with type 1 diabetes who have suboptimal control, but is still far from a cure.
  Medscape Medical News, October 2018
• Novo Nordisk to Cut 250 Jobs in the United States Denmark's Novo Nordisk will cut around 250 jobs in the United States, a spokesman told Reuters on Friday, adding the drugmaker would also hire an as-yet undetermined number of staff to new positions.
  Reuters Health Information, September 2018
• Alert Possible Pen Needle Confusion Prompts FDA Safety Alert The FDA has received reports of patients using standard pen needles to inject insulin without removing the inner needle cover, leading to patient harm in some cases.
  News Alerts, September 2018
• EASD 2018It's Personal: EASD Focuses on Individualizing Diabetes Care Providing data for clinicians to help individualize diabetes treatment is one aim of the European Association for the Study of Diabetes (EASD) 2018 Annual Meeting.
  Medscape Medical News, September 2018
• Gla-300 Comparable to IDeg-100 for Uncontrolled Type 2 Diabetes A head-to-head study of glargine 300 units/mL (Gla-300) and degludec 100 units/mL (IDeg-100) showed that both of these second-generation basal insulin analogs were comparable for treating uncontrolled type 2 diabetes, although hypoglycemia rates were lower with Gla-300 during the titration period, researchers say.
  Reuters Health Information, September 2018
• DIY Artificial Pancreas Users Tweet it 'Changes Lives' Study based on use of the #OpenAPS Twitter hashtag suggests that users of the DIY hack of an insulin pump and continuous glucose monitor perceive it as effective, safe, and life changing.
  Medscape Medical News, September 2018
• Majority of Patients in Poorer Nations Not Taking Diabetes Meds Availability, affordability of essential diabetes medicines is still poor in low- and middle-income countries, with a new analysis from PURE indicating only 30% of patients are taking them.
  Medscape Medical News, September 2018
• WHO Issues Cost-Conscious Diabetes Treatment Guidelines World Health Organization guidelines target therapy for type 1 and type 2 diabetes in low-resource settings, differing in several ways from advice of the American College of Physicians.
  Medscape Medical News, September 2018
• Semaglutide Promising in Phase II Weight Loss Trial Obese patients experienced superior weight loss while taking semaglutide compared with liraglutide or placebo, in a phase 2 trial.
  Reuters Health Information, September 2018
• ADA Issues New Guidance on Type 1 Diabetes in Youth 'There are unique challenges that children and their families face. We have tried to provide a comprehensive approach to that,' says an author.
  Medscape Medical News, August 2018
• Little Difference Between Basal Insulin Analogs for Type 2 Diabetes Evidence comparing old versus new insulin analogs is poor quality. There are 'many options' and 'high price tags' but 'little ability to discern the potential benefits of one...versus another,' said one commentator.
  Medscape Medical News, July 2018
• Alert Deaths From Fentanyl, Fentanyl Analogs Have Risen Sharply Deaths from fentanyl and fentanyl analogs, such as carfentanil, have more than doubled since 2015, the CDC reports. The increase is a result of increased supply of the drugs and their mixture with heroin.
  News Alerts, July 2018
• ADA 2018Liraglutide: A New Player in Type 1 Diabetes Treatment? In a randomized, placebo-controlled trial, liraglutide added to insulin improved glycemic control and reduced weight and blood pressure.
  Medscape Medical News, July 2018
• ADA 2018Investigational Tube-Free Pump for U-500 Insulin: A Viable Option The specially designed device by the makers of Omnipod may help avoid dosing errors in patients with type 2 diabetes requiring high doses of insulin.
  Medscape Medical News, July 2018
• ADA 2018New ADA/EASD Guidance on Diabetes: Assess CV Status First An upcoming document from the ADA and EASD will advise that selection of type 2 diabetes drug should be based on comorbidities and patient preferences.
  Medscape Medical News, June 2018
• ADA 2018Artificial Pancreas Helps Inpatients With Type 2 Diabetes A fully closed-loop automated insulin delivery system improved glycemic control without causing hypoglycemia in noncritically ill inpatients with type 2 diabetes.
  Medscape Medical News, June 2018
• ADA 2018Youth-Onset Diabetes Needs Different Approach to That in Adults Disturbing findings from the RISE study show that treating youth who have prediabetes with insulin and/or metformin doesn't prevent beta-cell deterioration; better treatments are needed, say physicians.
  Medscape Medical News, June 2018
• ADA 2018Flash Continuous-Glucose-Monitoring System Shows Real-World Benefits The Freestyle Libre continuous glucose monitoring (CGM) system from Abbott appears to have significant benefits for patients with diabetes, according to several late-breaking research abstracts presented by Abbott researchers at the American Diabetes Association (ADA) annual meeting in Orlando, Florida.
  Reuters Health Information, June 2018
• Lilly's Jardiance Meets Main Goal in Type 1 Diabetes Patients Eli Lilly & Co said on Monday that its drug Jardiance (empagliflozin), along with insulin therapy, met the main goal of two trials testing it in patients with type 1 diabetes, a population for which it is not presently approved.
  Reuters Health Information, June 2018
• ADA 2018Novel Systems Could Expand 'Hybrid Closed-Loop' Field in Diabetes  Three novel investigational hybrid closed-loop insulin delivery systems improve blood glucose and, if approved, will greatly increase options for patients with type 1 diabetes.
  Medscape Medical News, June 2018